Cargando…

Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study

The effects of sorafenib for Chinese patients with metastatic renal cell cancer (mRCC) were evaluated to figure out the relationship between clinical variables and prognosis. The data were analyzed retrospectively from six comprehensive cancer centers in Northeast China. All cases were diagnosed as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Fang, Han, Tao, Liu, Zhaozhe, Song, Xishuang, Zhang, Qifu, Kong, Xiangbo, Li, Changfu, Li, Zhenhua, Li, Chengge, Qu, Shuxian, Zheng, Zhendong, Piao, Ying, Han, Yaling, Xie, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489821/ https://www.ncbi.nlm.nih.gov/pubmed/26170693 http://dx.doi.org/10.2147/OTT.S84994

Ejemplares similares

Breast cancer metastasis to the stomach confirmed using gastroscopy: A case report
por: TAN, LINSHEN, et al.
Publicado: (2014)

Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients
por: Liu, Liang, et al.
Publicado: (2013)

SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression
por: Wang, Lu, et al.
Publicado: (2013)

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway
por: Du, Cheng, et al.
Publicado: (2014)

High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer
por: Han, Tao, et al.
Publicado: (2015)

miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance
por: Han, Tao, et al.
Publicado: (2020)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Numerical simulation of closed plastic impeller molding process and its parameter optimization
por: Fang, Mingyue, et al.
Publicado: (2022)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
por: Lu, Lu, et al.
Publicado: (2013)

Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma
por: Chow, Pierce K. H., et al.
Publicado: (2014)

Meta-analysis of the association between APC promoter methylation and colorectal cancer
por: Ding, Zhenyu, et al.
Publicado: (2015)

As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
por: Liu, Lei, et al.
Publicado: (2019)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis
por: Nishikawa, Hiroki, et al.
Publicado: (2017)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment
por: Kim, Seok Bae
Publicado: (2021)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?
por: Lock, Michael, et al.
Publicado: (2021)

Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation
por: Jiang, Yuchuan, et al.
Publicado: (2021)

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5
por: Wei, Xin, et al.
Publicado: (2018)

Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial
por: Yu, Yimin, et al.
Publicado: (2013)

Different imaging techniques for the detection of pelvic lymph nodes metastasis from gynecological malignancies: a systematic review and meta-analysis
por: Gong, Yi, et al.
Publicado: (2016)

Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6
por: JI, FAHE, et al.
Publicado: (2014)

Anti-tumor effect of chitin oligosaccharide plus cisplatin in vitro and in vivo
por: Liu, Xing, et al.
Publicado: (2019)

ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression
por: Liu, Junqiang, et al.
Publicado: (2022)

Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection
por: Tan, Yifei, et al.
Publicado: (2022)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells
por: Cao, J.Y., et al.
Publicado: (2017)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study
por: Hu, Hao, et al.
Publicado: (2015)

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib
por: Dranitsaris, G., et al.
Publicado: (2012)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_goqascr33vup07s0efec8kuerr